Marriam Ali,Pauline M Camacho
Marriam Ali
The diagnosis and management of premenopausal low bone mass or osteoporosis is challenging as its relationship to low bone mass and risk of fracture is less defined. Premenopausal or perimenopausal women with low bone density or a history o...
Optimal Management of Osteoporosis in the Spinal Cord (Injury) Population [0.03%]
脊髓（损伤）人群骨质疏松症的优化管理
Caroline Poku,Julie Fedorko,Frances M Weaver
Caroline Poku
Spinal cord injury (SCI) leads to significant bone loss resulting in osteoporosis and an increased risk of fractures below the level of injury. It is imperative to screen for osteoporosis in all individuals with SCI starting immediately aft...
Sumeet Jain
Sumeet Jain
Denosumab rebound-associated fractures occur in approximately 1 out of 14 patients who discontinue denosumab therapy without sequential antiresorptive therapy. They occur due to excessive bone resorption after missed or delayed denosumab do...
Utility of Trabecular Bone Score in the Management of Patients with Osteoporosis [0.03%]
trabecular骨密度评分在 osteoporosis患者管理中的作用
E Michael Lewiecki
E Michael Lewiecki
Trabecular bone score (TBS) enhances assessment of fracture risk in older women and men across many race/ethnicities and with a broad range of comorbidities. The best validated clinical utility of TBS is for input in the FRAX algorithm to m...
An Update on the Fracture Risk Assessment Tool: What Have We Learned over 15+ years? [0.03%]
骨折风险评估工具的更新：15年来的经验教训是什么？
Laura T Dickens,Rajesh K Jain
Laura T Dickens
The Fracture Risk Assessment Tool (FRAX) was launched in 2008 and uses clinical variables to estimate 10-year fracture risk. FRAX has been incorporated into clinical treatment guidelines and is well validated in specific disease states like...
Pinar Jaclyn Smith
Pinar Jaclyn Smith
Osteoporosis is treated similarly in all patients with GFR greater than 30 mL/min. In patients with fragility fracture with a GFR less than 30 mL/min, correct diagnosis through biopsy and bone turnover markers of adynamic bone disease, hype...
Luigi di Filippo,Clifford J Rosen
Luigi di Filippo
In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Relat...
Prathayini Subarajan,Rod Marianne Arceo-Mendoza,Pauline M Camacho
Prathayini Subarajan
Osteoporosis is characterized by increased bone turnover and reduced bone mass, leading to skeletal fragility and heightened fracture risk. It is a growing public health concern with expectations for a continued significant rise of fracture...
Rachel Pessah-Pollack,Maria Papaleontiou
Rachel Pessah-Pollack
Robert Rapaport
Robert Rapaport